表紙
市場調查報告書

第一型糖尿病:流行病學的預測

Type 1 Diabetes: Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 876685
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
第一型糖尿病:流行病學的預測 Type 1 Diabetes: Epidemiology Forecast to 2026
出版日期: 2019年04月30日內容資訊: 英文 29 Pages
簡介

本報告提供全球主要8個國家 (8MM:美國、加拿大、法國、德國、義大利、西班牙、英國、日本) 的第一型糖尿病的發病情形與今後預測相關分析,疾病的特徵,及目前患病者的總數與趨勢 (各年齡層、男女趨勢),今後10年的趨勢預測等調查。

第1章 目錄

第2章 第一型糖尿病:摘要整理

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全世界的趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
  • 第一型糖尿病的流行病學的預測 (今後11年份)
    • 第一型糖尿病的已受診患病人數 (總數)
    • 第一型糖尿病的已受診患病人數:各年齡層
    • 第一型糖尿病的已受診患病人數:男女
  • 討論
    • 流行病學性的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER202-19

Type 1 diabetes, formerly referred to as insulin-dependent diabetes, is a type of diabetes that predominantly develops in children or young adults before the age of 40 years. The condition, therefore, was also referred to as juvenile diabetes. Type 1 diabetes accounts for about 5-10% of all diabetes cases and occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin, a hormone that regulates blood sugar. If the condition is left untreated, blood sugar levels accumulate. In addition to the pancreas, high levels of blood sugar can damage other major organs, such as the heart, blood vessels, nerves, eyes, and kidneys. Such damage can be life threatening. Furthermore, research suggests that the incidence of type 1 diabetes is increasing globally, which may lead to an increased burden on healthcare resources (Holt, 2004; World Health Organization, 2013; Mayo Clinic, 2017).

To forecast the diagnosed prevalent cases of type 1 diabetes in the 8MM, GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of type 1 diabetes in the 8MM.

In the 8MM, the diagnosed prevalent cases of type 1 diabetes will increase from 3,396,254 cases in 2016 to 4,725,990 cases in 2026, at an Annual Growth Rate (AGR) of 3.92% per year. Among the 8MM, the US had the highest number of diagnosed prevalent cases of type 1 diabetes in 2016 and 2026, at 1,564,973 cases and 2,274,873 cases, respectively. Canada had the lowest number of prevalent cases of type 1 diabetes in 2016 and 2026, at 163,113 cases and 254,166 cases, respectively. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases of type 1 diabetes in the 8MM to environmental factors (seasonal variation) coupled with genetic factors, such as a family history of type 1 diabetes. However, further research is necessary to clearly understand the epidemiological factors responsible for the growth in the prevalent cases of type 1 diabetes (Onkamo et al., 1999).

Scope

  • The Type 1 Diabetes Epidemiology Report provides an overview of the risk factors and global trends of type 1 diabetes in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of type 1 diabetes segmented by age (ages under 20 years, 20-29 years, 30-44 years, 45-59 years, 60-74 years, and 75 years and older) and sex in these markets. To forecast the diagnosed prevalent cases of type 1 diabetes in the 8MM, GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of type 1 diabetes in the 8MM.
  • The type 1 diabetes epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Type 1 Diabetes Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes market.
  • Quantify patient populations in the global type 1 diabetes market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for type 1 diabetes therapeutics in each of the markets covered.

Table of Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Type 1 Diabetes: Executive Summary
    • 2.1 Related Reports
    • 2.2 Upcoming Reports
  • 3 Epidemiology
    • 3.1 Disease Background
    • 3.2 Risk Factors and Comorbidities
    • 3.3 Global and Historical Trends
    • 3.4 Forecast Methodology
      • 3.4.1 Sources
      • 3.4.2 Forecast Assumptions and Methods
    • 3.5 Epidemiological Forecast for Type 1 Diabetes (2016-2026)
      • 3.5.1 Diagnosed Prevalent Cases of Type 1 Diabetes
      • 3.5.2 Age-Specific Diagnosed Prevalent Cases of Type 1 Diabetes
      • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of Type 1 Diabetes
    • 3.6 Discussion
      • 3.6.1 Epidemiological Forecast Insight
      • 3.6.2 Limitations of the Analysis
      • 3.6.3 Strengths of the Analysis
  • 4 Appendix
    • 4.1 Bibliography
    • 4.2 Abbreviations
    • 4.3 About the Authors
      • 4.3.1 Epidemiologist
      • 4.3.2 Reviewers
      • 4.3.3 Global Director of Therapy Analysis and Epidemiology
      • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
    • 4.4 About GlobalData
    • 4.5 Contact Us
    • 4.6 Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Type 1 Diabetes

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, Both Sexes, N, 2016 and 2026
  • Figure 2: 8MM, Diagnosed Prevalence (%) of Type 1 Diabetes, Men, All Ages, 2006-2026
  • Figure 3: 8MM, Diagnosed Prevalence (%) of Type 1 Diabetes, Women, All Ages, 2006-2026
  • Figure 4: 8MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Type 1 Diabetes
  • Figure 5: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, Both Sexes, N, 2016
  • Figure 6: 8MM, Age-Specific Diagnosed Prevalent Cases of Type 1 Diabetes, Both Sexes, N, 2016
  • Figure 7: 8MM, Sex-Specific Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, N, 2016
Back to Top